About - 3-D Matrix

Company Overview

Since the inceptions of 3-D Matrix as a spinoff from MIT in 2004, 3-D Matrix has grown to become leading global peptide solutions company headquartered in Tokyo, Japan. With offices serving the Americas, Europe and Asia our employees together with our partners and distributor serve research scientists, healthcare providers and patients around the globe.

The location of 3-D Matrix offices across the world

1990s

In the early 90’s MIT post-doctoral researcher Shuguang Zhang observed a unusual repeating peptide sequence, whilst studying the peptide Zuotin, which binds to Z-DNA.

This unusual repeating sequence led to the discovery of self-assembling peptides.

This was a completely new field for use in medical applications.

2001

In 2001 3-D Matrix Inc, was established in Boston MA, USA by Scientific Founders at MIT, to whom MIT granted exclusive worldwide license. This facility had the aim of advancing the ambitious product development programme of PuraStat. Today this research and development facility continues working to expand the indications for PuraStat and to develop new complementary products and therapies.

PuraStat

2004

In 2004 3-D Matrix Limited, was founded in Japan and received license from 3-D Matrix Inc.

Research collaborations with 3rd party institutions gathered pace and new applications for the product pipeline were identified.

2007

In 2007 MIT and Scientific Founders agreed the acquisition of 3-D Matrix, Inc (USA) by 3-D Matrix Limited (Japan). This enabled product development to speed up and allowed 3-D Matrix to develop the business into a global company.

2008

First clinical cases of PuraStat

PuraStat was first used in clinical trials this year, further excelling product development and enabling 3-D Matrix to continue to develop as a global company.

2011

In 2011 the successful IPO (initial Public Offering) of 3-D Matrix Limited (Japan) was completed on the Japanese Stock Exchange.

2013

In 2013 The European Central Facility was established in Lyon, France.

2014

In 2014 PuraStat received its CE Mark and sales in EU begin.

World-Map-Vector-partner-locations-01

2015

3-D Matrix continues to expand it’s global footprint with the appointment of several partners around the globe.

2016

TGA registration and first units of PuraStat sold in Australia via a local distributor.

2019

2019 was a year of global expansion!

PuraBond received its CE Mark and sales in EU begin.
Whilst in the US, PuraSinus also goes to market at the end of 2019.
In Australia, 3-D Matrix Medical Technology Pty Ltd is formed allowing PuraStat to be sold direct in the Australian market. It is the first region for 3-D Matrix to employ a direct to market strategy.

2021

2021 was an exciting year for 3-D Matrix, with several large milestones being achieved, including:

PuraStat-GI 510 (k) cleared by FDA in US for gastrointestinal endoscopic procedures.
PuraStat was approved for the listing on Japan’s National Health Insurance Price List for use in gastrointestinal endoscopic procedures.
First human clinical investigation of the next generation self-assembling haemostat.

Keiji Nagano // Chairman and Executive Director

After working at ExxonMobil Corporation and then Bain & Company, Nagano started taking part in New Media as the director of New Media Japan Inc. in 2000. While he was vice-president of the Tokyo office of Bain & Co., he also played a key role as the director of the South Korea office for four years in establishing the office. He led projects with clients in various lines of businesses and gained wide experience in communications, high technology, entertainment, and the healthcare businesses at Bain & Co. Moreover, he supported foreign capital companies to launch businesses in Japan and carried them toward success by understanding them at the operational level on the lines.

He graduated from the Faculty of Technology at the University of Tokyo (chemical engineering) and earned a master’s degree in business economics (MBA) at Columbia University.

Jun Okada // President and Representative Director

He started working as a consultant at the Tokyo office of Bain & Co. in 1998, and was engaged in many projects, including bio investment support for a venture capital company and development support for a pharmaceutical company (as a resident person for a year). In 2005, he started taking charge of the corporate planning of 3-D Matrix and took up the post as director in 2007,and assumed his current position in 2016.

He graduated from the Law Faculty of the University of Tokyo and earned a master’s degree in business economics (MBA) at the INSEAD in France.

Tomoyuki Arai // Finance Director

In 1996, He started working at Pronexus Inc. (specialist of supporting corporate disclosure) and was involved in the tasks of many listed companies and those targeting IPOs. Since 2006, he was engaged in consulting services for IPOs and internal control systems at the CSBA consulting group. In 2007, he became a director of CSBA Investment. Subsequently, he was responsible for achieving the IPO (JASDAQ) for Ascot Corp. in 2008. He started serving in the sections for compliance and corporate planning at 3-D Matrix in 2008 and assumed the post of director in July 2012.

Toshi Amanuma // Business Director (North America)

Toshi started his career at strategy consulting firm Bain & Company, and continued to gain experience at Sony Corporation, 3-D Matrix and JBIC IG Partners. Recently, he served as managing director of 3-D Matrix EMEA, responsible for commercializing 3-D Matrix’s first medical device product across the EMEA region, and as managing director at JBIC IG Partners, a fund GP subsidiary of Japanese government-owned bank JBIC (Japan Bank of International Cooperation), involved in making fund investments and leading fund formation projects. Toshi rejoined 3-D Matrix in August 2019 to lead the US subsidiary, 3-D Matrix, Inc.

Toshi received his MBA from the Tuck School of Business at Dartmouth College, and his MS from Waseda University.

Andy Kim // Business Executive Officer (Asia Oceania)

Andy is equipped with various experience in multinational healthcare companies such as Pfizer, Baxter. Before joining 3-D Matrix in 2016, he worked for Baxter Healthcare as Senior Business Manager Asia-Pacific. He lead significant projects such as conducting market research, developing business roadmaps, and designing and executing brand lifecycle plans, new product launches, and market entrance strategies in partnership with country-level teams in +10 countries across the Asia Pacific. He also specializes in cross-functional online facilitation, profit plans on country/regional base. He earned Master’s degree in Business Administration (MBA) from Georgetown University in Washington, D.C. after bachelor’s degree in Hankuk University of Foreign Studies in Seoul.

Marie Buffier // R&D Executive Officer (Europe)

She obtained her PhD in Biology, Cancer Research & Endocrinology from the Claude Bernard University of Lyon, France, in 2008. She then worked as a Postdoctoral Research Fellow in USA first at the Medical Center at University of Rochester and then at the New York University Langone Medical Center elucidating the mechanisms of inflammation in the esophageal cancer formation.

She joined 3-D Matrix Europe in 2013 as the Project Manager of External collaboration and set-up multiple collaborations with academics groups and surgeons to expand new applications of 3-D Matrix' peptides technology. She then lead the development of new products in Europe as the Director of Research and Development in 2019 and is holding her current position since 2021.